With new products showing signs of impressive growth, Eli Lilly seems safely past the company’s recent patent trough.
Nine years ago Keytruda was about to be out-licensed. Now Keytruda is Merck’s top-selling medicine.
The long-term strategy of Novartis is concentrated on becoming a leading medicines company powered by data and digital.
As patents expire for Novo Nordisk’s top-selling products, the company is trying to bolster the pipeline with collaborations and a complete reorganization of R&D operations.
While advancing original biologics and new molecular entities, Pfizer also has been gaining rapid approvals of biosimilar drugs and has reorganized business units for future success.
Roche is developing the company’s internal capabilities and building strategic partnerships ready for the next stage in personalized healthcare.
Executives continue to have faith in Sanofi’s strategic plans to get the company to new heights despite continued impact from patent expirations.
HBA’s 2018 Annual Conference will be held in Washington, D.C. on November 5-6.
